Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-06-14

Clinical Trial Update: NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing NKTR-102 to irinotecan in second-line, irinotecan-naïve, KRAS-mutant colorectal cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Irinotecan (Irinotecan)
  • NKTR-102

Snippet

Sponsor: Nektar Therapeutics | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-06-14